BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//talks.cam.ac.uk//v3//EN
BEGIN:VTIMEZONE
TZID:Europe/London
BEGIN:DAYLIGHT
TZOFFSETFROM:+0000
TZOFFSETTO:+0100
TZNAME:BST
DTSTART:19700329T010000
RRULE:FREQ=YEARLY;BYMONTH=3;BYDAY=-1SU
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0100
TZOFFSETTO:+0000
TZNAME:GMT
DTSTART:19701025T020000
RRULE:FREQ=YEARLY;BYMONTH=10;BYDAY=-1SU
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
CATEGORIES:Seminars on Quantitative Biology @ CRUK Cambridge 
 Institute 
SUMMARY:Cell-of-origin of prostate cancer and clinical het
 erogeneity - Dr Esther Baena from CRUK Manchester 
 Institute 
DTSTART;TZID=Europe/London:20181217T130000
DTEND;TZID=Europe/London:20181217T140000
UID:TALK114076AThttp://talks.cam.ac.uk
URL:http://talks.cam.ac.uk/talk/index/114076
DESCRIPTION:Personalized treatment for prostate cancer remains
  a challenge because there are no clear molecular 
 subtypes to guide patient response. Imaging\, PSA 
 levels and pathological assessment of biopsies thr
 ough the Gleason grading system remain the gold st
 andard for diagnosis and risk stratification. More
 over\, most genomic campaigns analysed single biop
 sies with reduce analysis of their cellular landsc
 ape\, which limit the value of this analysis in wh
 at is known to be a multifocal disease. By combini
 ng genomic and multiparametric imaging analysis of
  high-risk prostate cancer patients\, we have char
 acterized the radiogenomic landscape of multifocal
  prostate cancer (Parry\, Srivastana\, Ali et al\,
  EU Oncology\, Oct 2018). Moreover\, coupling sing
 le-cell profiling and functional characterization 
 by organoid-culture and in situ lineage-tracing an
 alysis in mouse models\, we have identified inhere
 ntly castration-resistant cellular subpopulations 
 in the prostate defined by their unique cell-surfa
 ce markers. In particular\, our studies define LY6
 D as a marker for prostate progenitors and castrat
 ion-resistant luminal cells\, which may serve as p
 rognostic maker for advanced prostate cancer (Barr
 os-Silva\, Linn\, Steiner\, in press). Further fun
 ctional characterisation of the identified therapy
 -resistant prostate luminal subpopulations will hi
 ghlight their contribution to tumour subtypes ther
 eby advancing patient stratification and setting a
  pipeline to develop novel therapeutics.
LOCATION:CRUK CI Lecture Theatre (Room 001)
CONTACT:
END:VEVENT
END:VCALENDAR